期刊文献+

Cypher与Taxus支架治疗冠心病的冠状动脉造影随访结果 被引量:1

Angiographic follow-up study of the effect of the Cypher and Taxus stents in coronary antery disease
下载PDF
导出
摘要 目的观察Cypher及Taxus药物洗脱支架治疗冠心病的疗效。方法应用冠状动脉造影随访162例接受Cypher及Taxus药物洗脱支架置入术的冠心病患者,其中Cypher组93例,Taxus组69例。结果Cypher组和Taxus组再狭窄率分别为10.8%和11.6%,靶病变再血管化率分别为5.4%和5.8%,两组比较差异均无统计学意义。支架内晚期管径丢失及支架节段晚期管径丢失在Cypher组低于Taxus组,两组间差异有统计学意义。结论药物洗脱支架可有效降低介入治疗术后再狭窄的发生率,但Cypher组支架内晚期管径丢失低于Taxus组。 Objective To evaluate the efficacy of Cypher and Taxus drug eluting stent (DES)in the treatment of coronary artery diease. Methods A total 162 patients underwent coronary artery stenting with eigher the Cypher (n=93) or the Taxus (n=69) drug eluting stent. All patients received follow up angiography. Results The angiographic restenosis rate and TLR rate were 10.8% and 5.4% in the Cypher group whereas 11.6% and 5.8% in the Taxus group. There were no statistical differences between the two groups. In-Stent Late Loss and In-Lesion Late Loss were found less in the Cypher group than in the Taxus group. Conclusion Both the Cypher DES and the Taxus DES decreased the restenosis and TLR rates but the Cypher stent has a lower late loss rate than the Taxus stent.
出处 《中国介入心脏病学杂志》 2005年第3期158-159,共2页 Chinese Journal of Interventional Cardiology
关键词 CYPHER Taxus支架 治疗 冠心病 冠状动脉造影 Stents Coronary disease Angioplasty, transluminal, percutaneous coronary
  • 相关文献

参考文献9

  • 1Serruys PW. ARTS Ⅰ-the rapamycin eluting stent; ARTS Ⅱ - the rosy prophecy. Eur Heart J, 2002,23:757-759.
  • 2Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versusstandard stents in patients with stenosis in a native coronary artery. N Engl J Med, 2003, 349:1315-1323.
  • 3Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slowrelease paclitaxel-eluting stent for de novo coronary lesions. Circulation, 2003,107:38-42.
  • 4Bauters C, Lablanche JM, Renaud N, et al. Morphological changes after percutaneous transluminal coronary angioplasty of unstable plaques: insights from serial angioscopic follow-up. Eur Heart J, 1996,17:1554-1559.
  • 5Ruygrok PN, Muller DW, Serruys PW. Rapamycin in cardiovascular medicine. Intern Med J, 2003,33:103-109.
  • 6Giannakakou P, Robey R, Fojo T, et al. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene, 2001,20:3806-3813.
  • 7Morice MC, Serruys PW, Sousa JE, et al. for the RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med, 2002,346:1773-1780.
  • 8Sousa JE, Costa MA, Sousa AG, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation, 2003,107:381-383.
  • 9Gregg W, Stephen G, David AC, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent the TAXUS-Ⅳ trial. Circulation, 2004,109:1942-1947.

同被引文献13

  • 1魏盟,马士新,陆志刚,蒋利,杭靖宇,张洁,李京波,顾水明,张昀昀,金立仁.冠心病患者应用紫杉醇与国产雷帕霉素洗脱支架的随机对照研究[J].中国循环杂志,2005,20(2):90-93. 被引量:16
  • 2张健,杜新平,卢才义,许强,侯允天,赵玉生,王士雯.雷帕霉素洗脱支架治疗老年冠状动脉特长病变的临床研究[J].心血管康复医学杂志,2005,14(3):228-230. 被引量:1
  • 3调查协作组,霍勇.中国多中心药物洗脱支架急性或亚急性血栓的调查[J].中国介入心脏病学杂志,2005,13(3):131-134. 被引量:24
  • 4陈纪林,高润霖,杨跃进,乔树宾,秦学文,姚民,刘海波,徐波,吴永健,袁晋青,陈珏,戴军,尤士杰,马卫华.雷帕霉素和紫杉醇药物洗脱支架治疗冠心病复杂病变的临床近远期疗效比较[J].中华医学杂志,2005,85(31):2183-2186. 被引量:11
  • 5Weisz G,Leon MB,Holmes DR,et al.Two-year outcomes after sirolimus-eluting stent implantation:results from the Sirolimus-eluting stent in de novo native coronary lesions(SIRIUS)trial[J].J Am Coll Cardiol,2006,47(7):1350-1355.
  • 6Stone GW,Ellis SG,Cox DA,et al. One-year clinical results with the slow-release,polymer-based,paclitaxel-eluting TAXUS stent:the TAXUS-IV trial[J].Circulation,2004,109(16):1942-1947.
  • 7Urban P,Gershlick AH,Guagliumi G,et al.Safety of coronary sirolimus-eluting stents in daily clinical practice:one-year follow-up of the e-Cypher registry[J].Circulation,2006,113(11):1434-1441.
  • 8Kastrati A,Dibra A,Mehilli J, et al.Predictive factors of restenosis after coronary implantation of sirolimus-or paclitax-eleluting stents[J].Circulation.2006,113(19):2293-2300.
  • 9Jang JS,Hong MK,Lee CW,et al.Comparison between sirolimus-and paclitaxel-eluting stents for the treatment of chronic total occlusions[J].J Invasive Cardiol,2006,18(5):205-208.
  • 10Sidhu S,Shafiq N,Mahotra S,et al.A meta-analysis of trials comparing Cypher and Taxus stents in patients with obstructive coronary artery disease[J].Br J Clin Pharmacol,2006,61(6):720-726.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部